Dimensional Fund Advisors LP cut its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 35.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 131,314 shares of the company's stock after selling 71,627 shares during the period. Dimensional Fund Advisors LP's holdings in Roivant Sciences were worth $1,553,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of the company. Barclays PLC increased its holdings in Roivant Sciences by 19.7% in the 3rd quarter. Barclays PLC now owns 459,521 shares of the company's stock worth $5,302,000 after purchasing an additional 75,609 shares in the last quarter. Elevate Capital Advisors LLC acquired a new position in shares of Roivant Sciences in the fourth quarter valued at approximately $2,116,000. Thompson Siegel & Walmsley LLC increased its stake in shares of Roivant Sciences by 10.1% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 565,337 shares of the company's stock valued at $6,688,000 after buying an additional 51,705 shares during the period. Russell Investments Group Ltd. raised its holdings in Roivant Sciences by 478.6% in the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after buying an additional 1,948 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Roivant Sciences during the 4th quarter worth approximately $995,000. 64.76% of the stock is currently owned by institutional investors.
Roivant Sciences Trading Up 0.5%
ROIV stock traded up $0.05 during trading on Monday, hitting $10.84. The company had a trading volume of 3,576,583 shares, compared to its average volume of 5,584,012. The business has a 50-day moving average of $10.51 and a 200-day moving average of $11.07. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $13.06. The stock has a market cap of $7.73 billion, a PE ratio of -72.26 and a beta of 1.23.
Wall Street Analyst Weigh In
ROIV has been the subject of several recent research reports. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Monday, April 21st.
Read Our Latest Stock Report on Roivant Sciences
Insider Activity at Roivant Sciences
In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the firm's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $10.65, for a total value of $1,065,000.00. Following the completion of the sale, the chief operating officer now directly owns 896,869 shares in the company, valued at approximately $9,551,654.85. This trade represents a 10.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Vivek Ramaswamy sold 273,959 shares of Roivant Sciences stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the completion of the sale, the insider now directly owns 39,799,611 shares of the company's stock, valued at approximately $456,501,538.17. This trade represents a 0.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,223,959 shares of company stock worth $13,420,035 over the last quarter. Company insiders own 7.90% of the company's stock.
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
See Also
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
